Targeting breast cancer using pirarubicin-loaded vasoactive intestinal peptide grafted sterically stabilized micelles

Eskandari Z., Bahadori F., Yapaoz M. A., Yenigun V. B., Celikten M., Kocyigit A., ...More

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol.162, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 162
  • Publication Date: 2021
  • Doi Number: 10.1016/j.ejps.2021.105830
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, Chemical Abstracts Core, EMBASE, International Pharmaceutical Abstracts, MEDLINE, Veterinary Science Database
  • Keywords: Nanomedicine, Sterically stabilized micelle, Pirarubicin, VIP, Targeted cancer therapy, IN-VITRO, PHOSPHOLIPID MICELLES, DRUG-DELIVERY, VIP, NANOMEDICINE, VIVO, INTERNALIZATION, DERIVATIVES, FORMULATION, RECEPTORS
  • Bezmialem Vakıf University Affiliated: Yes


In this study the chemotherapeutic agent Pirarubicin (PRB) which is known for its serious side effects was actively targeted to the breast cancer cells by uploading it to the biocompatible and biodegradable Sterically Stabilized Micelles (SSMs) made of 1,2-Distearoyl-sn-glycero-3 phosphoethanolamine-N-methoxy-polyethylene glycol 2000 (DSPE-PEG(2000)) to enhance efficacy and reduce toxicity. Vasoactive intestinal peptide (VIP), the receptors of which are overexpressed on the breast cancer cells, was grafted on the surface of the micelles. To the best of our knowledge this is the first report on active targeting of PRB to tumor site.